AromaDb: A Database of Plant's Aroma Molecules

Warfarin Details

: IUPAC Name
4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one
:Chemical Class
Ketone
:CAS Registry Number
81-81-2
:Description

:Fragrance Type

Physical and Chemical properties

PUBCHEM ID54678486
Molecular Weight (mg/mol)308.328
Molecular FormulaC19H16O4
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count4
Rotatable Bond Count4
IUPAC Name4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one
Canonical SMILESCC(=O)CC(c1ccccc1)c3c(O)c2ccccc2oc3=O
PUBCHEM IUPAC INCHIKEYPJVWKTKQMONHTI-UHFFFAOYSA-N
Solubility Level3
Vapour Pressure-7.486

Absorption and Metabolism information

XLOGP3 AA
CACTVS TPSA63.6
BBB Level2
Absorption Level0
EXT PPB#Prediction1
AlogP982.827
EXT CYP2D6#Prediction1

Toxicological Information

Mouse Female FDANon-Carcinogen
Mouse Male FDASingle-Carcinogen
Rat Female FDANon-Carcinogen
Rat Male FDANon-Carcinogen
Ames PredictionNon-Mutagen
Developmental / Reproductive ToxicityNon-Toxic
Rat Oral LD500.337299 g/kg_body_weight
Ocular IrritancyMild
Hepatotoxic#Prediction1
Effected Human Genes

Ecological Information

Aerobic Biodegradability PredictionDegradable

Hazard(s) Identification

Physical hazardsnot classified
Health hazards None
Environmental hazardsnot classified
About Table Headings

Compound Biological Activity

Serial No.Cas No Gene SymbolOrganismInteraction Interaction ActionsPubMed Id
1 81-81-2 CYP2C9 Homo sapiens 10-hydroxywarfarin binds to and results in decreased activity of CYP2C9 protein affects^binding|decreases^activity 20429590
2 81-81-2 CYP2C9 Homo sapiens [10-hydroxywarfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP2C9 mRNA affects^binding|increases^activity|increases^expression 20735727
3 81-81-2 CYP3A4 Homo sapiens [10-hydroxywarfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA affects^binding|increases^activity|increases^expression 20735727
4 81-81-2 NR1I2 Homo sapiens 10-hydroxywarfarin binds to and results in increased activity of NR1I2 protein affects^binding|increases^activity 20735727
5 81-81-2 UGT2B7 Homo sapiens 10-hydroxywarfarin binds to and results in decreased activity of UGT2B7 protein affects^binding|decreases^activity 25393417
6 81-81-2 UGT2B7 Homo sapiens [10-hydroxywarfarin binds to and results in decreased activity of UGT2B7 protein] which results in decreased glucuronidation of Zidovudine affects^binding|decreases^activity|decreases^glucuronidation 25393417
7 81-81-2 CYP2C9 Homo sapiens 4'-hydroxywarfarin binds to and results in decreased activity of CYP2C9 protein affects^binding|decreases^activity 20429590
8 81-81-2 CYP2C9 Homo sapiens [4'-hydroxywarfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP2C9 mRNA affects^binding|increases^activity|increases^expression 20735727
9 81-81-2 CYP3A4 Homo sapiens [4'-hydroxywarfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA affects^binding|increases^activity|increases^expression 20735727
10 81-81-2 NR1I2 Homo sapiens 4'-hydroxywarfarin binds to and results in increased activity of NR1I2 protein affects^binding|increases^activity 20735727
11 81-81-2 UGT2B7 Homo sapiens 4'-hydroxywarfarin binds to and results in decreased activity of UGT2B7 protein affects^binding|decreases^activity 25393417
12 81-81-2 UGT2B7 Homo sapiens [4'-hydroxywarfarin binds to and results in decreased activity of UGT2B7 protein] which results in decreased glucuronidation of Zidovudine affects^binding|decreases^activity|decreases^glucuronidation 25393417
13 81-81-2 CYP2C9 Homo sapiens 6-hydroxywarfarin results in decreased activity of CYP2C9 protein decreases^activity 20429590
14 81-81-2 UGT2B7 Homo sapiens 6-hydroxywarfarin binds to UGT2B7 protein affects^binding 25393417
15 81-81-2 CYP2C9 Homo sapiens 7-hydroxywarfarin results in decreased activity of CYP2C9 protein decreases^activity 20429590
16 81-81-2 UGT2B7 Homo sapiens 7-hydroxywarfarin binds to and results in decreased activity of UGT2B7 protein affects^binding|decreases^activity 25393417
17 81-81-2 UGT2B7 Homo sapiens [7-hydroxywarfarin binds to and results in decreased activity of UGT2B7 protein] which results in decreased glucuronidation of Zidovudine affects^binding|decreases^activity|decreases^glucuronidation 25393417
18 81-81-2 CYP2C9 Homo sapiens 8-hydroxywarfarin results in decreased activity of CYP2C9 protein decreases^activity 20429590
19 81-81-2 UGT2B7 Homo sapiens 8-hydroxywarfarin binds to UGT2B7 protein affects^binding 25393417
20 81-81-2 ABCB1 Homo sapiens ABCB1 polymorphism affects the susceptibility to Warfarin affects^response to substance 24092646|25312789
21 81-81-2 ABCC6 Mus musculus ABCC6 gene mutant form results in increased susceptibility to Warfarin increases^response to substance 23415960
22 81-81-2 ABCC6 Mus musculus [Magnesium deficiency co-treated with Phosphates] promotes the reaction [ABCC6 gene mutant form results in increased susceptibility to Warfarin] affects^cotreatment|increases^reaction|increases^response to substance 23415960
23 81-81-2 ABCG2 Homo sapiens ABCG2 SNP affects the susceptibility to Warfarin affects^response to substance 25300812
24 81-81-2 ACTA2 Rattus norvegicus [Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of ACTA2 mRNA affects^cotreatment|increases^expression 23117658
25 81-81-2 ACTB Mus musculus Warfarin results in decreased expression of ACTB mRNA decreases^expression 20493250
26 81-81-2 ACTB Mus musculus Warfarin results in increased expression of ACTB mRNA increases^expression 20493250
27 81-81-2 ACTR3 Mus musculus Warfarin results in increased expression of ACTR3 mRNA increases^expression 20493250
28 81-81-2 AHCY Mus musculus Warfarin results in decreased expression of AHCY mRNA decreases^expression 20493250
29 81-81-2 AKT1 Rattus norvegicus 6-N,N-diethyl-beta,gamma-dibromomethylene-D-ATP inhibits the reaction [[Warfarin co-treated with Phosphates] results in decreased phosphorylation of AKT1 protein] affects^cotreatment|decreases^phosphorylation|decreases^reaction 22659116
30 81-81-2 AKT1 Rattus norvegicus Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased phosphorylation of AKT1 protein] affects^cotreatment|decreases^phosphorylation|decreases^reaction 27212383
31 81-81-2 AKT1 Rattus norvegicus [Warfarin co-treated with Phosphates] results in decreased phosphorylation of AKT1 protein affects^cotreatment|decreases^phosphorylation 22659116
32 81-81-2 AKT1 Rattus norvegicus [Warfarin co-treated with Vitamin K 1] results in decreased phosphorylation of AKT1 protein affects^cotreatment|decreases^phosphorylation 27212383
33 81-81-2 ALB Homo sapiens Aspirin inhibits the reaction [Warfarin binds to ALB protein] affects^binding|decreases^reaction 25499135
34 81-81-2 ALB Homo sapiens prodan inhibits the reaction [Warfarin binds to ALB protein] affects^binding|decreases^reaction 12044178
35 81-81-2 ALB Homo sapiens Pyruvaldehyde inhibits the reaction [Warfarin binds to ALB protein] affects^binding|decreases^reaction 20934417
36 81-81-2 ALB Homo sapiens Warfarin binds to ALB protein affects^binding 19596536|20934417|20956006|25499135
37 81-81-2 ALB Homo sapiens [Warfarin binds to ALB protein] inhibits the reaction [copper (II) diacetyl-di(N(4)-methylthiosemicarbazone) binds to ALB protein] affects^binding|decreases^reaction 18937368
38 81-81-2 ALB Homo sapiens [Warfarin binds to ALB protein] inhibits the reaction [copper pyruvaldehyde bis(N(4)-methylthiosemicarbazone) complex binds to ALB protein] affects^binding|decreases^reaction 18937368
39 81-81-2 ALB Rattus norvegicus Warfarin results in decreased expression of ALB protein decreases^expression 22342526
40 81-81-2 ALOX5AP Homo sapiens Warfarin results in increased expression of ALOX5AP mRNA increases^expression 16698924
41 81-81-2 ALPL Mus musculus Warfarin inhibits the reaction [BMP2 protein results in increased activity of ALPL protein] decreases^reaction|increases^activity 21910061
42 81-81-2 ALPL Mus musculus Warfarin inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA] decreases^reaction|increases^expression 21910061
43 81-81-2 ALPL Mus musculus Warfarin inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA] decreases^reaction|increases^expression 21910061
44 81-81-2 ANXA4 Mus musculus Warfarin results in decreased expression of ANXA4 mRNA decreases^expression 20493250
45 81-81-2 ANXA5 Mus musculus Warfarin results in decreased expression of ANXA5 mRNA decreases^expression 20493250
46 81-81-2 APOE Homo sapiens APOE gene mutant form affects the susceptibility to Warfarin affects^response to substance 21228733
47 81-81-2 APOE Homo sapiens APOE gene polymorphism affects the susceptibility to Warfarin affects^response to substance 16847429|17048007|17325732
48 81-81-2 APOE Homo sapiens APOE polymorphism affects the susceptibility to Warfarin affects^response to substance 25312789
49 81-81-2 APOE Homo sapiens APOE protein affects the susceptibility to Warfarin affects^response to substance 15952022
50 81-81-2 APOE Homo sapiens APOE SNP affects the susceptibility to Warfarin affects^response to substance 28079798
51 81-81-2 APOE Mus musculus APOE gene mutant form results in increased susceptibility to Warfarin increases^response to substance 23415960
52 81-81-2 ARHGDIA Mus musculus Warfarin results in increased expression of ARHGDIA mRNA increases^expression 20493250
53 81-81-2 ARSE Gallus gallus Warfarin results in decreased activity of ARSE protein decreases^activity 15246527
54 81-81-2 AXIN2 Rattus norvegicus Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of AXIN2 mRNA] affects^cotreatment|decreases^reaction|increases^expression 23117658
55 81-81-2 AXIN2 Rattus norvegicus Quercetin inhibits the reaction [Warfarin results in increased expression of AXIN2 mRNA] decreases^reaction|increases^expression 23117658
56 81-81-2 AXIN2 Rattus norvegicus [Warfarin co-treated with Vitamin K] results in increased expression of AXIN2 mRNA affects^cotreatment|increases^expression 23117658
57 81-81-2 AXIN2 Rattus norvegicus Warfarin results in increased expression of AXIN2 mRNA increases^expression 23117658
58 81-81-2 AXL Homo sapiens AXL protein promotes the reaction [Warfarin results in increased susceptibility to gemcitabine] increases^reaction|increases^response to substance 26206560
59 81-81-2 AXL Homo sapiens AXL protein results in increased susceptibility to Warfarin increases^response to substance 26206560
60 81-81-2 AXL Homo sapiens Vitamin K inhibits the reaction [Warfarin results in decreased expression of AXL protein modified form] decreases^expression|decreases^reaction 26206560
61 81-81-2 AXL Homo sapiens Warfarin inhibits the reaction [GAS6 protein results in increased activity of AXL protein] decreases^reaction|increases^activity 26206560
62 81-81-2 AXL Homo sapiens Warfarin results in decreased expression of AXL protein decreases^expression 26206560
63 81-81-2 AXL Homo sapiens Warfarin results in decreased expression of AXL protein modified form decreases^expression 26206560
64 81-81-2 AXL Rattus norvegicus Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased expression of AXL protein] affects^cotreatment|decreases^expression|decreases^reaction 27212383
65 81-81-2 AXL Rattus norvegicus [Warfarin co-treated with Vitamin K 1] results in decreased expression of AXL protein affects^cotreatment|decreases^expression 27212383
66 81-81-2 BCL2 Rattus norvegicus Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased expression of BCL2 protein] affects^cotreatment|decreases^expression|decreases^reaction 27212383
67 81-81-2 BCL2 Rattus norvegicus [Warfarin co-treated with Vitamin K 1] results in decreased expression of BCL2 protein affects^cotreatment|decreases^expression 27212383
68 81-81-2 BGLAP Mus musculus Warfarin inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein] decreases^reaction|increases^activity 21910061
69 81-81-2 BGLAP Mus musculus Warfarin inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA] decreases^reaction|increases^expression 21910061
70 81-81-2 BGLAP Mus musculus Warfarin inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA] decreases^reaction|increases^expression 21910061
71 81-81-2 BGLAP Rattus norvegicus Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of BGLAP mRNA] affects^cotreatment|decreases^reaction|increases^expression 23117658
72 81-81-2 BGLAP Rattus norvegicus Quercetin inhibits the reaction [Warfarin results in increased expression of BGLAP mRNA] decreases^reaction|increases^expression 23223575
73 81-81-2 BGLAP Rattus norvegicus [Warfarin co-treated with Vitamin K] results in increased expression of BGLAP mRNA affects^cotreatment|increases^expression 23117658
74 81-81-2 BGLAP Rattus norvegicus Warfarin results in increased expression of BGLAP mRNA increases^expression 23223575
75 81-81-2 BMP2 Mus musculus Warfarin inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein] decreases^reaction|increases^activity 21910061
76 81-81-2 BMP2 Mus musculus Warfarin inhibits the reaction [BMP2 protein results in increased expression of COL1A1 mRNA] decreases^reaction|increases^expression 21910061
77 81-81-2 BMP2 Mus musculus Warfarin inhibits the reaction [BMP2 protein results in increased expression of SP7 mRNA] decreases^reaction|increases^expression 21910061
78 81-81-2 BMP2 Rattus norvegicus Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 mRNA] affects^cotreatment|affects^expression|affects^reaction 27412937
79 81-81-2 BMP2 Rattus norvegicus Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 protein] affects^cotreatment|affects^expression|affects^reaction 27412937
80 81-81-2 BMP2 Rattus norvegicus [Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 mRNA affects^cotreatment|affects^expression 27412937
81 81-81-2 BMP2 Rattus norvegicus [Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 protein affects^cotreatment|affects^expression 27412937
82 81-81-2 C1QBP Mus musculus Warfarin results in increased expression of C1QBP mRNA increases^expression 20493250
83 81-81-2 CALR Mus musculus Warfarin results in increased expression of CALR mRNA increases^expression 20493250
84 81-81-2 CALU Homo sapiens CALU polymorphism affects the susceptibility to Warfarin affects^response to substance 20200517
85 81-81-2 CALU Rattus norvegicus CALU protein results in decreased susceptibility to Warfarin decreases^response to substance 11641264
86 81-81-2 CASP3 Homo sapiens Warfarin results in increased expression of CASP3 protein modified form increases^expression 26206560
87 81-81-2 CASP3 Mus musculus [Warfarin co-treated with Vitamin K 1] results in increased cleavage of CASP3 protein affects^cotreatment|increases^cleavage 23990204
88 81-81-2 CASP3 Mus musculus Warfarin results in decreased expression of CASP3 mRNA decreases^expression 20493250
89 81-81-2 CASP3 Rattus norvegicus Warfarin results in increased expression of CASP3 mRNA increases^expression 19815060
90 81-81-2 CAT Rattus norvegicus Warfarin results in increased activity of CAT protein increases^activity 22342526
91 81-81-2 CCND1 Rattus norvegicus Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of CCND1 mRNA] affects^cotreatment|decreases^reaction|increases^expression 23117658
92 81-81-2 CCND1 Rattus norvegicus Quercetin inhibits the reaction [Warfarin results in increased expression of CCND1 mRNA] decreases^reaction|increases^expression 23117658
93 81-81-2 CCND1 Rattus norvegicus [Warfarin co-treated with Vitamin K] results in increased expression of CCND1 mRNA affects^cotreatment|increases^expression 23117658
94 81-81-2 CCND1 Rattus norvegicus Warfarin results in increased expression of CCND1 mRNA increases^expression 23117658
95 81-81-2 CCT5 Mus musculus Warfarin results in increased expression of CCT5 mRNA increases^expression 20493250
96 81-81-2 CCT6A Mus musculus Warfarin results in increased expression of CCT6A mRNA increases^expression 20493250
97 81-81-2 CCT8 Mus musculus Warfarin results in decreased expression of CCT8 mRNA decreases^expression 20493250
98 81-81-2 CDC42 Mus musculus Warfarin results in decreased expression of CDC42 mRNA decreases^expression 20493250
99 81-81-2 CDH1 Homo sapiens Warfarin results in increased expression of CDH1 protein increases^expression 26206560
100 81-81-2 CLIC1 Mus musculus Warfarin results in decreased expression of CLIC1 mRNA decreases^expression 20493250
101 81-81-2 CNN1 Rattus norvegicus [Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of CNN1 mRNA affects^cotreatment|increases^expression 23117658
102 81-81-2 COL1A1 Rattus norvegicus Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of COL1A1 mRNA] affects^cotreatment|decreases^reaction|increases^expression 23117658
103 81-81-2 COL1A1 Rattus norvegicus Quercetin inhibits the reaction [Warfarin results in increased expression of COL1A1 mRNA] decreases^reaction|increases^expression 23223575
104 81-81-2 COL1A1 Rattus norvegicus [Warfarin co-treated with Vitamin K] results in increased expression of COL1A1 mRNA affects^cotreatment|increases^expression 23117658
105 81-81-2 COL1A1 Rattus norvegicus Warfarin results in increased expression of COL1A1 mRNA increases^expression 23223575
106 81-81-2 COX5A Mus musculus Warfarin results in increased expression of COX5A mRNA increases^expression 20493250
107 81-81-2 CRK Mus musculus Warfarin results in increased expression of CRK mRNA increases^expression 20493250
108 81-81-2 CTNNB1 Homo sapiens Warfarin results in decreased expression of and affects the localization of CTNNB1 protein affects^localization|decreases^expression 26206560
109 81-81-2 CTNNB1 Rattus norvegicus CTNNB1 protein affects the susceptibility to Warfarin affects^response to substance 23223575
110 81-81-2 CTNNB1 Rattus norvegicus Quercetin inhibits the reaction [Warfarin results in increased expression of and affects the localization of CTNNB1 protein] affects^localization|decreases^reaction|increases^expression 23117658
111 81-81-2 CTNNB1 Rattus norvegicus Warfarin results in increased expression of and affects the localization of CTNNB1 protein affects^localization|increases^expression 23117658
112 81-81-2 CXCL8 Warfarin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of CXCL8 mRNA] decreases^reaction|increases^expression 24603311
113 81-81-2 CYP1A1 Mus musculus Warfarin results in decreased activity of CYP1A1 protein decreases^activity 18420780
114 81-81-2 CYP1A2 Homo sapiens CYP1A2 SNP affects the susceptibility to Warfarin affects^response to substance 28079798
115 81-81-2 CYP2A4 Mus musculus Warfarin results in decreased activity of CYP2A4 protein decreases^activity 18420780
116 81-81-2 CYP2B10 Mus musculus Warfarin results in decreased activity of CYP2B10 protein decreases^activity 18420780
117 81-81-2 CYP2C18 Homo sapiens CYP2C18 gene polymorphism affects the susceptibility to Warfarin affects^response to substance 19752777
118 81-81-2 CYP2C18 Homo sapiens CYP2C18 protein affects the susceptibility to Warfarin affects^response to substance 19752777
119 81-81-2 CYP2C19 Homo sapiens CYP2C19 gene polymorphism affects the metabolism of and affects the susceptibility to Warfarin affects^metabolic processing|affects^response to substance 25652102
120 81-81-2 CYP2C19 Homo sapiens CYP2C19 gene polymorphism affects the susceptibility to Warfarin affects^response to substance 19752777
121 81-81-2 CYP2C19 Homo sapiens CYP2C19 polymorphism affects the susceptibility to Warfarin affects^response to substance 27356304
122 81-81-2 CYP2C19 Homo sapiens CYP2C19 protein affects the susceptibility to Warfarin affects^response to substance 19752777
123 81-81-2 CYP2C19 Macaca fascicularis CYP2C19 protein polymorphism affects the susceptibility to Warfarin affects^response to substance 25036290
124 81-81-2 CYP2C29 Mus musculus Warfarin results in decreased activity of CYP2C29 protein decreases^activity 18420780
125 81-81-2 CYP2C9 Homo sapiens CYP2C9 affects the susceptibility to Warfarin affects^response to substance 22907842
126 81-81-2 CYP2C9 Homo sapiens CYP2C9 gene affects the susceptibility to Warfarin affects^response to substance 11127854|11307788|14676821|15001971|15284536|15371982|19207028
127 81-81-2 CYP2C9 Homo sapiens CYP2C9 gene mutant form affects the susceptibility to Warfarin affects^response to substance 20354686|21261182|21428138
128 81-81-2 CYP2C9 Homo sapiens CYP2C9 gene mutant form results in increased susceptibility to Warfarin increases^response to substance 25994031|26255664
129 81-81-2 CYP2C9 Homo sapiens CYP2C9 gene polymorphism affects the susceptibility to and affects the metabolism of Warfarin affects^metabolic processing|affects^response to substance 26469104
130 81-81-2 CYP2C9 Homo sapiens CYP2C9 gene polymorphism affects the susceptibility to Warfarin affects^response to substance 14656880|14691573|15050794|15100169|15900281|15900282|15940194|16432637|16611750|16676068|16708125|16847429|16878445|16890578|16960144|17048007|17049586|17111199|17387222|17456829|17496169|17672075|17764537|18370846|18429757|18535201|18542936|18574025|18698879|18756910|18776969|18836275|19300499|19567378|19745563|19998810|20386359|20615525|20677151|20842355|21110192|21228733|21590310|21681008|22198820|22528326|23376925|24474498|25298588|25521356|25652102|25699611|25747538|25866574|25904339|26418980|26502504|27581200
131 81-81-2 CYP2C9 Homo sapiens CYP2C9 gene polymorphism results in decreased susceptibility to Warfarin decreases^response to substance 18030307|18034619
132 81-81-2 CYP2C9 Homo sapiens CYP2C9 gene polymorphism results in increased susceptibility to Warfarin increases^response to substance 11794436|19899329
133 81-81-2 CYP2C9 Homo sapiens CYP2C9 gene SNP affects the susceptibility to Warfarin affects^response to substance 20442691|20653674|20833655|20854800|21270790|21320153|21321468|21326313|21451434|21562147|21635147|21639946|22266406|26223945|26568290
134 81-81-2 CYP2C9 Homo sapiens CYP2C9 polymorphism affects the susceptibility to Warfarin affects^response to substance 17510308|17895500|17955230|18570163|20072124|20339978|20637959|20884456|21713378|21786578|21911247|22040439|22161100|22248286|22274142|22533669|22594507|22855348|23061746|23159229|23167228|23183958|23208322|23276529|23279643|23602689|23688605|23710884|23990957|24956244|24978953|25042728|25312789|26940072|27055637
135 81-81-2 CYP2C9 Homo sapiens CYP2C9 protein affects the susceptibility to Warfarin affects^response to substance 15952022|17456829|18034618|19745563|19752777|20375999|22990331|24750390
136 81-81-2 CYP2C9 Homo sapiens CYP2C9 protein polymorphism affects the susceptibility to Warfarin affects^response to substance 23800980|24601977|25075423
137 81-81-2 CYP2C9 Homo sapiens CYP2C9 protein results in increased susceptibility to Warfarin increases^response to substance 17049586|17111199|17387222|17496169|18542936
138 81-81-2 CYP2C9 Homo sapiens CYP2C9 results in increased susceptibility to Warfarin increases^response to substance 20420818
139 81-81-2 CYP2C9 Homo sapiens CYP2C9 SNP affects the susceptibility to Warfarin affects^response to substance 24966969|28079798
140 81-81-2 CYP2C9 Homo sapiens CYP2C9 SNP affects the susceptibility to Warfarin analog affects^response to substance 25499099
141 81-81-2 CYP2C9 Homo sapiens Simvastatin affects the reaction [CYP2C9 polymorphism affects the susceptibility to Warfarin] affects^reaction|affects^response to substance 22594507
142 81-81-2 CYP2C9 Homo sapiens [Warfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP2C9 mRNA affects^binding|increases^activity|increases^expression 20735727
143 81-81-2 CYP2C9 Homo sapiens Warfarin results in decreased activity of CYP2C9 protein decreases^activity 18420780
144 81-81-2 CYP2D6 Homo sapiens Warfarin results in decreased activity of CYP2D6 protein decreases^activity 18420780
145 81-81-2 CYP3A2 Rattus norvegicus CYP3A2 mRNA affects the susceptibility to Warfarin affects^response to substance 11531004
146 81-81-2 CYP3A2 Rattus norvegicus Warfarin results in increased expression of CYP3A2 mRNA increases^expression 11531004
147 81-81-2 CYP3A4 Homo sapiens CYP3A4 SNP affects the susceptibility to Warfarin affects^response to substance 28079798
148 81-81-2 CYP3A4 Homo sapiens [Warfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA affects^binding|increases^activity|increases^expression 20735727
149 81-81-2 CYP3A4 Homo sapiens Warfarin results in decreased activity of CYP3A4 protein decreases^activity 18420780
150 81-81-2 CYP3A5 Homo sapiens CYP3A5 gene polymorphism affects the susceptibility to Warfarin affects^response to substance 19752777
151 81-81-2 CYP3A5 Homo sapiens CYP3A5 protein affects the susceptibility to Warfarin affects^response to substance 19752777
152 81-81-2 CYP3A65 Danio rerio Warfarin results in increased expression of CYP3A65 mRNA increases^expression 25094061
153 81-81-2 CYP4F2 Homo sapiens CYP4F2 gene affects the susceptibility to Warfarin affects^response to substance 19207028
154 81-81-2 CYP4F2 Homo sapiens CYP4F2 gene mutant form affects the susceptibility to Warfarin affects^response to substance 20553802
155 81-81-2 CYP4F2 Homo sapiens CYP4F2 gene polymorphism affects the susceptibility to Warfarin affects^response to substance 18250228|19270263|19300499|20217574|22172097|22192158|22198820|22528326|22892446|26418980
156 81-81-2 CYP4F2 Homo sapiens [CYP4F2 gene polymorphism co-treated with VKORC1 gene mutant form] affects the susceptibility to Warfarin affects^cotreatment|affects^response to substance 21084764
157 81-81-2 CYP4F2 Homo sapiens CYP4F2 gene SNP affects the susceptibility to Warfarin affects^response to substance 20442691|20833655|21326313|21562147|25747538|26223945
158 81-81-2 CYP4F2 Homo sapiens CYP4F2 polymorphism affects the susceptibility to Warfarin affects^response to substance 20653676|23061746|25042728
159 81-81-2 CYP4F2 Homo sapiens CYP4F2 protein polymorphism affects the susceptibility to Warfarin affects^response to substance 23215885
160 81-81-2 CYP4F2 Homo sapiens CYP4F2 protein results in increased susceptibility to Warfarin increases^response to substance 18250228
161 81-81-2 CYP4F2 Homo sapiens CYP4F2 SNP affects the susceptibility to Warfarin affects^response to substance 28079798
162 81-81-2 DCTN2 Mus musculus Warfarin results in decreased expression of DCTN2 mRNA decreases^expression 20493250
163 81-81-2 DDT Mus musculus Warfarin results in decreased expression of DDT mRNA decreases^expression 20493250
164 81-81-2 DLST Mus musculus Warfarin results in decreased expression of DLST mRNA decreases^expression 20493250
165 81-81-2 DOCK7 Mus musculus Warfarin results in increased expression of DOCK7 mRNA increases^expression 20493250
166 81-81-2 DPYSL2 Mus musculus Warfarin results in increased expression of DPYSL2 mRNA increases^expression 20493250
167 81-81-2 DSTN Mus musculus Warfarin results in decreased expression of DSTN mRNA decreases^expression 20493250
168 81-81-2 EEF2 Mus musculus Warfarin results in decreased expression of EEF2 mRNA decreases^expression 20493250
169 81-81-2 EIF3I Mus musculus Warfarin results in decreased expression of EIF3I mRNA decreases^expression 20493250
170 81-81-2 EMCN Homo sapiens Warfarin results in decreased expression of EMCN protein decreases^expression 26206560
171 81-81-2 ENPP1 Rattus norvegicus Warfarin results in increased expression of ENPP1 mRNA increases^expression 22659116
172 81-81-2 ENPP1 Rattus norvegicus Warfarin results in increased expression of ENPP1 protein increases^expression 22659116
173 81-81-2 EPHX1 Homo sapiens EPHX1 gene polymorphism affects the susceptibility to Warfarin affects^response to substance 17496169|20842355
174 81-81-2 EPHX1 Homo sapiens EPHX1 gene SNP affects the susceptibility to Warfarin affects^response to substance 15900282|25629049
175 81-81-2 EPHX1 Homo sapiens EPHX1 intron SNP affects the susceptibility to Warfarin affects^response to substance 21192345
176 81-81-2 EPHX1 Homo sapiens EPHX1 polymorphism affects the susceptibility to Warfarin affects^response to substance 24092646
177 81-81-2 EPHX1 Homo sapiens EPHX1 protein results in increased susceptibility to Warfarin increases^response to substance 17496169
178 81-81-2 EPHX1 Homo sapiens EPHX1 SNP affects the susceptibility to Warfarin affects^response to substance 28079798
179 81-81-2 ERP29 Mus musculus Warfarin results in decreased expression of ERP29 mRNA decreases^expression 20493250
180 81-81-2 F10 Rattus norvegicus Warfarin results in decreased activity of F10 protein decreases^activity 20371969
181 81-81-2 F2 Homo sapiens F2 gene polymorphism affects the susceptibility to Warfarin affects^response to substance 14656880
182 81-81-2 F2 Homo sapiens Fenofibrate promotes the reaction [Warfarin results in decreased expression of F2 protein] decreases^expression|increases^reaction 9681093
183 81-81-2 F2 Homo sapiens Warfarin results in decreased expression of F2 protein decreases^expression 9681093
184 81-81-2 F5 Homo sapiens F5 gene polymorphism affects the susceptibility to Warfarin affects^response to substance 19752777
185 81-81-2 F5 Homo sapiens F5 protein affects the susceptibility to Warfarin affects^response to substance 19752777
186 81-81-2 F7 Homo sapiens F7 gene mutant form affects the susceptibility to Warfarin affects^response to substance 20885134
187 81-81-2 F7 Homo sapiens F7 gene polymorphism affects the susceptibility to Warfarin affects^response to substance 14656880
188 81-81-2 F7 Homo sapiens Fenofibrate promotes the reaction [Warfarin results in decreased expression of F7 protein] decreases^expression|increases^reaction 9681093
189 81-81-2 F7 Homo sapiens Warfarin results in decreased expression of F7 protein decreases^expression 9681093
190 81-81-2 F7 Rattus norvegicus Warfarin results in decreased activity of F7 protein decreases^activity 20371969
191 81-81-2 FPGS Homo sapiens FPGS gene polymorphism affects the susceptibility to Warfarin affects^response to substance 25079360
192 81-81-2 FSCN1 Mus musculus Warfarin results in decreased expression of FSCN1 mRNA decreases^expression 20493250
193 81-81-2 G3BP1 Mus musculus Warfarin results in increased expression of G3BP1 mRNA increases^expression 20493250
194 81-81-2 GALE Mus musculus Warfarin results in decreased expression of GALE mRNA decreases^expression 20493250
195 81-81-2 GAS6 Rattus norvegicus Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased expression of GAS6 protein] affects^cotreatment|decreases^expression|decreases^reaction 27212383
196 81-81-2 GAS6 Rattus norvegicus [Warfarin co-treated with Vitamin K 1] results in decreased expression of GAS6 protein affects^cotreatment|decreases^expression 27212383
197 81-81-2 GAS6 Rattus norvegicus Warfarin results in decreased expression of GAS6 protein decreases^expression 19564549
198 81-81-2 GDI2 Mus musculus Warfarin results in increased expression of GDI2 mRNA increases^expression 20493250
199 81-81-2 GGCX Danio rerio Warfarin results in increased expression of GGCX mRNA increases^expression 25094061
200 81-81-2 GGCX Homo sapiens GGCX gene polymorphism affects the susceptibility to Warfarin affects^response to substance 17049586|17496169|17764537
201 81-81-2 GGCX Homo sapiens GGCX gene polymorphism results in decreased susceptibility to Warfarin decreases^response to substance 16676068
202 81-81-2 GGCX Homo sapiens GGCX gene SNP affects the susceptibility to Warfarin affects^response to substance 21195460|21326313
203 81-81-2 GGCX Homo sapiens GGCX polymorphism affects the susceptibility to Warfarin affects^response to substance 22161100|25042728
204 81-81-2 GGCX Homo sapiens GGCX protein results in increased susceptibility to Warfarin increases^response to substance 17049586|17496169
205 81-81-2 GMPS Mus musculus Warfarin results in increased expression of GMPS mRNA increases^expression 20493250
206 81-81-2 GSK3B Rattus norvegicus Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased phosphorylation of GSK3B protein] affects^cotreatment|decreases^reaction|increases^phosphorylation 23117658
207 81-81-2 GSK3B Rattus norvegicus [Warfarin co-treated with Vitamin K] results in increased phosphorylation of GSK3B protein affects^cotreatment|increases^phosphorylation 23117658
208 81-81-2 HDAC1 Mus musculus Warfarin results in increased expression of HDAC1 mRNA increases^expression 20493250
209 81-81-2 HINT1 Mus musculus Warfarin results in increased expression of HINT1 mRNA increases^expression 20493250
210 81-81-2 HMOX1 Rattus norvegicus Warfarin affects the expression of HMOX1 mRNA affects^expression 22954530
211 81-81-2 HNRNPAB Mus musculus Warfarin results in increased expression of HNRNPAB mRNA increases^expression 20493250
212 81-81-2 HNRNPDL Mus musculus Warfarin results in decreased expression of HNRNPDL mRNA decreases^expression 20493250
213 81-81-2 HNRNPF Mus musculus Warfarin results in increased expression of HNRNPF mRNA increases^expression 20493250
214 81-81-2 HNRNPK Mus musculus Warfarin results in decreased expression of HNRNPK mRNA decreases^expression 20493250
215 81-81-2 HNRNPK Mus musculus Warfarin results in increased expression of HNRNPK mRNA increases^expression 20493250
216 81-81-2 HP Rattus norvegicus Warfarin results in increased expression of HP protein increases^expression 22342526
217 81-81-2 HSP90AB1 Mus musculus Warfarin results in decreased expression of HSP90AB1 mRNA decreases^expression 20493250
218 81-81-2 HSPA8 Mus musculus Warfarin results in increased expression of HSPA8 mRNA increases^expression 20493250
219 81-81-2 HSPD1 Mus musculus Warfarin results in increased expression of HSPD1 mRNA increases^expression 20493250
220 81-81-2 IFNG Warfarin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of IFNG mRNA] increases^expression|increases^reaction 24603311
221 81-81-2 IL12A Rattus norvegicus Warfarin results in increased expression of IL12A mRNA increases^expression 22342526
222 81-81-2 IL12B Rattus norvegicus Warfarin results in increased expression of IL12B mRNA increases^expression 22342526
223 81-81-2 IL1B Homo sapiens Warfarin inhibits the reaction [Vitamin K 2 results in decreased susceptibility to IL1B protein] decreases^reaction|decreases^response to substance 20460758
224 81-81-2 IL1B Rattus norvegicus [Warfarin co-treated with Vitamin K] results in increased expression of IL1B mRNA affects^cotreatment|increases^expression 23117658
225 81-81-2 IL1B Warfarin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL1B mRNA] decreases^reaction|increases^expression 24603311
226 81-81-2 IL2 Warfarin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL2 mRNA] increases^expression|increases^reaction 24603311
227 81-81-2 IL6 Mus musculus Warfarin results in decreased expression of IL6 protein decreases^expression 18772604
228 81-81-2 IL6 Rattus norvegicus [Warfarin co-treated with Vitamin K] results in increased expression of IL6 mRNA affects^cotreatment|increases^expression 23117658
229 81-81-2 IL6 Rattus norvegicus Warfarin results in decreased expression of IL6 mRNA decreases^expression 26742017
230 81-81-2 IL6 Rattus norvegicus Warfarin results in increased expression of IL6 protein increases^expression 22342526
231 81-81-2 IPO5 Mus musculus Warfarin results in decreased expression of IPO5 mRNA decreases^expression 20493250
232 81-81-2 ISYNA1 Mus musculus Warfarin results in increased expression of ISYNA1 mRNA increases^expression 20493250
233 81-81-2 KRT18 Mus musculus Warfarin results in decreased expression of KRT18 mRNA decreases^expression 20493250
234 81-81-2 LASP1 Mus musculus Warfarin results in decreased expression of LASP1 mRNA decreases^expression 20493250
235 81-81-2 MGP Danio rerio Warfarin results in increased expression of MGP mRNA increases^expression 25094061
236 81-81-2 MGP Mus musculus [Warfarin co-treated with Vitamin K 1] results in decreased activity of MGP protein affects^cotreatment|decreases^activity 23990204
237 81-81-2 MGP Mus musculus [Warfarin co-treated with Vitamin K 1] results in decreased carboxylation of MGP protein affects^cotreatment|decreases^carboxylation 23990204
238 81-81-2 MGP Mus musculus [[Warfarin co-treated with Vitamin K 1] results in decreased carboxylation of MGP protein] which results in decreased activity of MGP protein affects^cotreatment|decreases^activity|decreases^carboxylation 23990204
239 81-81-2 MGP Mus musculus [Warfarin co-treated with Vitamin K 1] results in decreased expression of MGP mRNA affects^cotreatment|decreases^expression 23990204
240 81-81-2 MGP Rattus norvegicus [Quercetin co-treated with Warfarin] results in decreased carboxylation of MGP protein affects^cotreatment|decreases^carboxylation 23223575
241 81-81-2 MGP Rattus norvegicus [Vitamin K co-treated with Warfarin] results in increased carboxylation of MGP protein affects^cotreatment|increases^carboxylation 23223575
242 81-81-2 MGP Rattus norvegicus Warfarin inhibits the reaction [Vitamin K 1 results in increased expression of and results in increased secretion of MGP protein modified form] decreases^reaction|increases^expression|increases^secretion 21705322
243 81-81-2 MGP Rattus norvegicus Warfarin results in decreased expression of and results in decreased secretion of MGP protein decreases^expression|decreases^secretion 21705322
244 81-81-2 MGP Rattus norvegicus Warfarin results in decreased expression of and results in decreased secretion of MGP protein modified form decreases^expression|decreases^secretion 21705322
245 81-81-2 MIR133A2 Homo sapiens MIR133A2 gene SNP affects the susceptibility to Warfarin affects^response to substance 26113018
246 81-81-2 MPO Rattus norvegicus Warfarin results in increased activity of MPO protein increases^activity 26742017
247 81-81-2 MYH1 Rattus norvegicus [Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of MYH1 mRNA affects^cotreatment|increases^expression 23117658
248 81-81-2 NMRAL1 Mus musculus Warfarin results in increased expression of NMRAL1 mRNA increases^expression 20493250
249 81-81-2 NQO1 Homo sapiens NQO1 gene SNP affects the susceptibility to Warfarin affects^response to substance 26257249|27581200
250 81-81-2 NQO1 Homo sapiens NQO1 polymorphism affects the susceptibility to Warfarin affects^response to substance 23215885
251 81-81-2 NR1I2 Danio rerio Warfarin results in increased expression of NR1I2 mRNA increases^expression 25094061
252 81-81-2 NR1I2 Homo sapiens Warfarin binds to and results in increased activity of NR1I2 protein affects^binding|increases^activity 20735727
253 81-81-2 NUCB1 Mus musculus Warfarin results in increased expression of NUCB1 mRNA increases^expression 20493250
254 81-81-2 NUMB Rattus norvegicus Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of NUMB mRNA] affects^cotreatment|decreases^reaction|increases^expression 23117658
255 81-81-2 NUMB Rattus norvegicus [Warfarin co-treated with Vitamin K] results in increased expression of NUMB mRNA affects^cotreatment|increases^expression 23117658
256 81-81-2 OAT Mus musculus Warfarin results in decreased expression of OAT mRNA decreases^expression 20493250
257 81-81-2 ORM1 Homo sapiens Chlorpromazine inhibits the reaction [Warfarin binds to ORM1 protein alternative form] affects^binding|decreases^reaction 8946472
258 81-81-2 ORM1 Homo sapiens Dipyridamole inhibits the reaction [Warfarin binds to ORM1 protein alternative form] affects^binding|decreases^reaction 8946472
259 81-81-2 ORM1 Homo sapiens Lidocaine inhibits the reaction [Warfarin binds to ORM1 protein alternative form] affects^binding|decreases^reaction 8946472
260 81-81-2 ORM1 Homo sapiens ORM1 gene polymorphism affects the susceptibility to Warfarin affects^response to substance 17496169
261 81-81-2 ORM1 Homo sapiens ORM1 polymorphism affects the susceptibility to Warfarin affects^response to substance 23208322
262 81-81-2 ORM1 Homo sapiens ORM1 protein results in increased susceptibility to Warfarin increases^response to substance 17496169
263 81-81-2 ORM1 Homo sapiens Progesterone inhibits the reaction [Warfarin binds to ORM1 protein alternative form] affects^binding|decreases^reaction 8946472
264 81-81-2 ORM1 Homo sapiens Warfarin binds to ORM1 protein alternative form affects^binding 8946472
265 81-81-2 PA2G4 Mus musculus Warfarin results in increased expression of PA2G4 mRNA increases^expression 20493250
266 81-81-2 PARP1 Homo sapiens Warfarin results in increased expression of PARP1 protein modified form increases^expression 26206560
267 81-81-2 PDGFB Rattus norvegicus Warfarin results in decreased expression of PDGFB mRNA decreases^expression 11290560
268 81-81-2 PDGFB Rattus norvegicus Warfarin results in decreased expression of PDGFB protein decreases^expression 11290560
269 81-81-2 PDIA3 Mus musculus Warfarin results in decreased expression of PDIA3 mRNA decreases^expression 20493250
270 81-81-2 PDIA3 Mus musculus Warfarin results in increased expression of PDIA3 mRNA increases^expression 20493250
271 81-81-2 PDIA4 Mus musculus Warfarin results in decreased expression of PDIA4 mRNA decreases^expression 20493250
272 81-81-2 PGAM1 Mus musculus Warfarin results in decreased expression of PGAM1 mRNA decreases^expression 20493250
273 81-81-2 PGAM1 Mus musculus Warfarin results in increased expression of PGAM1 mRNA increases^expression 20493250
274 81-81-2 PKM Mus musculus Warfarin results in decreased expression of PKM mRNA decreases^expression 20493250
275 81-81-2 POR Homo sapiens POR gene SNP affects the susceptibility to Warfarin affects^response to substance 27488389
276 81-81-2 PPP1CA Mus musculus Warfarin results in decreased expression of PPP1CA mRNA decreases^expression 20493250
277 81-81-2 PPP2R1A Mus musculus Warfarin results in increased expression of PPP2R1A mRNA increases^expression 20493250
278 81-81-2 PROC Homo sapiens PROC gene polymorphism affects the susceptibility to Warfarin affects^response to substance 17048007|17496169
279 81-81-2 PROC Homo sapiens PROC protein results in increased susceptibility to Warfarin increases^response to substance 17496169
280 81-81-2 PROS1 Homo sapiens PROS1 gene polymorphism affects the susceptibility to Warfarin affects^response to substance 19752777
281 81-81-2 PROS1 Homo sapiens PROS1 protein affects the susceptibility to Warfarin affects^response to substance 19752777
282 81-81-2 PROS1 Rodentia PROS1 protein results in decreased susceptibility to Warfarin decreases^response to substance 22290807
283 81-81-2 PRSS53 Homo sapiens PRSS53 gene SNP affects the susceptibility to Warfarin affects^response to substance 21590310
284 81-81-2 PSMA3 Mus musculus Warfarin results in decreased expression of PSMA3 mRNA decreases^expression 20493250
285 81-81-2 PSMA6 Mus musculus Warfarin results in decreased expression of PSMA6 mRNA decreases^expression 20493250
286 81-81-2 PSMC2 Mus musculus Warfarin results in decreased expression of PSMC2 mRNA decreases^expression 20493250
287 81-81-2 PTH Mus musculus Warfarin results in decreased activity of PTH protein decreases^activity 11564701
288 81-81-2 RAB1A Mus musculus Warfarin results in decreased expression of RAB1A mRNA decreases^expression 20493250
289 81-81-2 RHOA Mus musculus Warfarin results in decreased expression of RHOA mRNA decreases^expression 20493250
290 81-81-2 RPL27 Mus musculus Warfarin results in increased expression of RPL27 mRNA increases^expression 20493250
291 81-81-2 RPL9 Mus musculus Warfarin results in increased expression of RPL9 mRNA increases^expression 20493250
292 81-81-2 RPLP0 Mus musculus Warfarin results in increased expression of RPLP0 mRNA increases^expression 20493250
293 81-81-2 RPSA Mus musculus Warfarin results in increased expression of RPSA mRNA increases^expression 20493250
294 81-81-2 RUNX1 Rattus norvegicus Quercetin inhibits the reaction [Warfarin results in increased expression of RUNX1 mRNA] decreases^reaction|increases^expression 23223575
295 81-81-2 RUNX1 Rattus norvegicus Warfarin results in increased expression of RUNX1 mRNA increases^expression 23223575
296 81-81-2 RUNX2 Rattus norvegicus Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 mRNA] affects^cotreatment|affects^expression|affects^reaction 27412937
297 81-81-2 RUNX2 Rattus norvegicus Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 protein] affects^cotreatment|affects^expression|affects^reaction 27412937
298 81-81-2 RUNX2 Rattus norvegicus Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of RUNX2 mRNA] affects^cotreatment|decreases^reaction|increases^expression 23117658
299 81-81-2 RUNX2 Rattus norvegicus [Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 mRNA affects^cotreatment|affects^expression 27412937
300 81-81-2 RUNX2 Rattus norvegicus [Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 protein affects^cotreatment|affects^expression 27412937
301 81-81-2 RUNX2 Rattus norvegicus [Warfarin co-treated with Vitamin K] results in increased expression of RUNX2 mRNA affects^cotreatment|increases^expression 23117658
302 81-81-2 RUVBL2 Mus musculus Warfarin results in decreased expression of RUVBL2 mRNA decreases^expression 20493250
303 81-81-2 SAE1 Mus musculus Warfarin results in decreased expression of SAE1 mRNA decreases^expression 20493250
304 81-81-2 SEPHS1 Mus musculus Warfarin results in increased expression of SEPHS1 mRNA increases^expression 20493250
305 81-81-2 SERPINC1 Homo sapiens Warfarin results in increased expression of SERPINC1 protein increases^expression 73932
306 81-81-2 SPP1 Mus musculus [Warfarin co-treated with Vitamin K 1] results in increased expression of SPP1 mRNA affects^cotreatment|increases^expression 23990204
307 81-81-2 SPP1 Rattus norvegicus [Quercetin co-treated with Warfarin] results in increased expression of SPP1 mRNA affects^cotreatment|increases^expression 23223575
308 81-81-2 SPP1 Rattus norvegicus [Warfarin co-treated with Vitamin K] results in increased expression of SPP1 mRNA affects^cotreatment|increases^expression 23117658
309 81-81-2 STIP1 Mus musculus Warfarin results in decreased expression of STIP1 mRNA decreases^expression 20493250
310 81-81-2 TAGLN Mus musculus [Warfarin co-treated with Vitamin K 1] results in decreased expression of TAGLN mRNA affects^cotreatment|decreases^expression 23990204
311 81-81-2 TAGLN Rattus norvegicus [Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of TAGLN mRNA affects^cotreatment|increases^expression 23117658
312 81-81-2 TCF4 Rattus norvegicus Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of TCF4 mRNA] affects^cotreatment|decreases^reaction|increases^expression 23117658
313 81-81-2 TCF4 Rattus norvegicus Quercetin inhibits the reaction [Warfarin results in increased expression of TCF4 mRNA] decreases^reaction|increases^expression 23117658
314 81-81-2 TCF4 Rattus norvegicus [Warfarin co-treated with Vitamin K] results in increased expression of TCF4 mRNA affects^cotreatment|increases^expression 23117658
315 81-81-2 TCF4 Rattus norvegicus Warfarin results in increased expression of TCF4 mRNA increases^expression 23117658
316 81-81-2 TCP1 Mus musculus Warfarin results in increased expression of TCP1 mRNA increases^expression 20493250
317 81-81-2 TGM2 Mus musculus TGM2 protein affects the susceptibility to Warfarin affects^response to substance 23117658
318 81-81-2 TGM2 Mus musculus [TGM2 protein affects the susceptibility to Warfarin] which affects the susceptibility to Quercetin affects^response to substance 23117658
319 81-81-2 TGM2 Mus musculus TGM2 protein results in increased susceptibility to Warfarin increases^response to substance 23117658
320 81-81-2 TGM2 Rattus norvegicus Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of and results in increased activity of TGM2 protein] affects^cotreatment|decreases^reaction|increases^activity|increases^expression 23117658
321 81-81-2 TGM2 Rattus norvegicus Quercetin inhibits the reaction [Warfarin results in increased activity of TGM2 protein] decreases^reaction|increases^activity 23117658
322 81-81-2 TGM2 Rattus norvegicus [Warfarin co-treated with Vitamin K] results in increased expression of and results in increased activity of TGM2 protein affects^cotreatment|increases^activity|increases^expression 23117658
323 81-81-2 TGM2 Rattus norvegicus Warfarin results in increased expression of and results in increased activity of TGM2 protein increases^activity|increases^expression 23117658
324 81-81-2 THOP1 Mus musculus Warfarin results in increased expression of THOP1 mRNA increases^expression 20493250
325 81-81-2 TNF Rattus norvegicus [Warfarin co-treated with Vitamin K] results in increased expression of TNF mRNA affects^cotreatment|increases^expression 23117658
326 81-81-2 TNF Rattus norvegicus Warfarin results in decreased expression of TNF mRNA decreases^expression 22342526|26742017
327 81-81-2 TNF Rattus norvegicus Warfarin results in increased expression of TNF increases^expression 21565690
328 81-81-2 TP53 Oryctolagus cuniculus Warfarin affects the expression of TP53 protein affects^expression 12872399
329 81-81-2 TSKU Danio rerio Warfarin results in increased expression of TSKU mRNA increases^expression 25094061
330 81-81-2 TUBA1A Mus musculus Warfarin results in increased expression of TUBA1A mRNA increases^expression 20493250
331 81-81-2 TUBA1B Mus musculus Warfarin results in decreased expression of TUBA1B mRNA decreases^expression 20493250
332 81-81-2 TUBA1B Mus musculus Warfarin results in increased expression of TUBA1B mRNA increases^expression 20493250
333 81-81-2 TUBB5 Mus musculus Warfarin results in decreased expression of TUBB5 mRNA decreases^expression 20493250
334 81-81-2 TUFM Mus musculus Warfarin results in decreased expression of TUFM mRNA decreases^expression 20493250
335 81-81-2 TYRO3 Mus musculus Warfarin results in decreased expression of TYRO3 mRNA decreases^expression 18772604
336 81-81-2 U2AF2 Mus musculus Warfarin results in increased expression of U2AF2 mRNA increases^expression 20493250
337 81-81-2 UGT1A1 Homo sapiens UGT1A1 gene SNP affects the susceptibility to Warfarin affects^response to substance 26223945
338 81-81-2 UGT1A1 Homo sapiens UGT1A1 polymorphism affects the susceptibility to Warfarin affects^response to substance 25312789
339 81-81-2 UGT1A1 Homo sapiens Warfarin binds to and results in decreased activity of UGT1A1 protein affects^binding|decreases^activity 25393417
340 81-81-2 UGT1A1 Homo sapiens [Warfarin binds to and results in decreased activity of UGT1A1 protein] which results in decreased glucuronidation of Estradiol affects^binding|decreases^activity|decreases^glucuronidation 25393417
341 81-81-2 UGT1A3 Homo sapiens Warfarin binds to and results in increased activity of UGT1A3 protein affects^binding|increases^activity 25393417
342 81-81-2 UGT1A3 Homo sapiens [Warfarin binds to and results in increased activity of UGT1A3 protein] which results in increased glucuronidation of vorinostat affects^binding|increases^activity|increases^glucuronidation 25393417
343 81-81-2 UGT1A7 Homo sapiens Warfarin binds to and affects the activity of UGT1A7 protein affects^activity|affects^binding 25393417
344 81-81-2 UGT1A7 Homo sapiens [Warfarin binds to and affects the activity of UGT1A7 protein] which affects the glucuronidation of Hymecromone affects^activity|affects^binding|affects^glucuronidation 25393417
345 81-81-2 UGT1A9 Homo sapiens Warfarin binds to and affects the activity of UGT1A9 protein affects^activity|affects^binding 25393417
346 81-81-2 UGT1A9 Homo sapiens [Warfarin binds to and affects the activity of UGT1A9 protein] which affects the glucuronidation of Propofol affects^activity|affects^binding|affects^glucuronidation 25393417
347 81-81-2 UGT2B17 Homo sapiens Warfarin binds to and results in decreased activity of UGT2B17 protein affects^binding|decreases^activity 25393417
348 81-81-2 UGT2B17 Homo sapiens [Warfarin binds to and results in decreased activity of UGT2B17 protein] which results in decreased glucuronidation of vorinostat affects^binding|decreases^activity|decreases^glucuronidation 25393417
349 81-81-2 UGT2B7 Homo sapiens Warfarin binds to and results in decreased activity of UGT2B7 protein affects^binding|decreases^activity 25393417
350 81-81-2 UGT2B7 Homo sapiens [Warfarin binds to and results in decreased activity of UGT2B7 protein] which results in decreased glucuronidation of Zidovudine affects^binding|decreases^activity|decreases^glucuronidation 25393417
351 81-81-2 USP5 Mus musculus Warfarin results in decreased expression of USP5 mRNA decreases^expression 20493250
352 81-81-2 VCP Mus musculus Warfarin results in decreased expression of VCP mRNA decreases^expression 20493250
353 81-81-2 VCP Mus musculus Warfarin results in increased expression of VCP mRNA increases^expression 20493250
354 81-81-2 VIM Homo sapiens Warfarin results in decreased expression of VIM protein decreases^expression 26206560
355 81-81-2 VKORC1 Danio rerio Warfarin results in increased expression of VKORC1 mRNA increases^expression 25094061
356 81-81-2 VKORC1 Homo sapiens VKORC1 3' UTR results in decreased susceptibility to Warfarin decreases^response to substance 16676068
357 81-81-2 VKORC1 Homo sapiens VKORC1 affects the susceptibility to Warfarin affects^response to substance 22907842
358 81-81-2 VKORC1 Homo sapiens VKORC1 gene affects the susceptibility to Warfarin affects^response to substance 15630486|19207028
359 81-81-2 VKORC1 Homo sapiens VKORC1 gene mutant form affects the susceptibility to Warfarin affects^response to substance 16879214|20354686|20553802|20716240|21228733|21428138
360 81-81-2 VKORC1 Homo sapiens VKORC1 gene mutant form results in decreased susceptibility to Warfarin decreases^response to substance 14765194|18266023|25885753
361 81-81-2 VKORC1 Homo sapiens VKORC1 gene polymorphism affects the susceptibility to Warfarin affects^response to substance 15578879|15930419|16270629|16432637|16611750|16847429|16890578|16960144|17048007|17049586|17111199|17329985|17387222|17391071|17456829|17496169|17764537|18370846|18532998|18535201|18542936|18574025|18698879|18776969|18805772|19018718|19135231|19300499|19567378|19998810|20386359|20579077|20615525|20842355|21110192|21681008|22198820|22528326|22533669|23990957|24399734|24474498|24978953|25652102|25699611|25747538|26167638|26219158|26418980
362 81-81-2 VKORC1 Homo sapiens VKORC1 gene polymorphism results in decreased susceptibility to Warfarin decreases^response to substance 17961434|18030307|18034619|19942260
363 81-81-2 VKORC1 Homo sapiens VKORC1 gene SNP affects the susceptibility to Warfarin affects^response to substance 20833655|20854800|21176721|21270790|21320153|21321468|21326313|21562147|21590310|21635147|21639946|22266406|26223945|26257249|26445138|26568290|26583785
364 81-81-2 VKORC1 Homo sapiens VKORC1 intron polymorphism affects the susceptibility to Warfarin affects^response to substance 15358623|18523153
365 81-81-2 VKORC1 Homo sapiens VKORC1 intron polymorphism results in increased susceptibility to Warfarin increases^response to substance 16676068
366 81-81-2 VKORC1 Homo sapiens VKORC1 intron SNP affects the susceptibility to Warfarin affects^response to substance 18240904
367 81-81-2 VKORC1 Homo sapiens VKORC1 polymorphism affects the susceptibility to Warfarin affects^response to substance 17510308|20072124|20339978|20637959|21786578|21911247|22040439|22161100|22248286|22855348|23061746|23167228|23183958|23208322|23276529|23279643|23602689|23710884|25042728|25312789|26940072|27055637
368 81-81-2 VKORC1 Homo sapiens VKORC1 promoter polymorphism affects the susceptibility to Warfarin affects^response to substance 18523153|22571356
369 81-81-2 VKORC1 Homo sapiens VKORC1 protein affects the susceptibility to Warfarin affects^response to substance 17456829|17995970|19752777|20375999|22990331|24750390|27938396
370 81-81-2 VKORC1 Homo sapiens VKORC1 protein polymorphism affects the susceptibility to Warfarin affects^response to substance 22266406|23800980|24601977|26757860
371 81-81-2 VKORC1 Homo sapiens VKORC1 protein results in increased susceptibility to Warfarin increases^response to substance 17049586|17111199|17387222|17496169|18532998|18542936
372 81-81-2 VKORC1 Homo sapiens VKORC1 protein SNP affects the susceptibility to Warfarin affects^response to substance 23571513
373 81-81-2 VKORC1 Homo sapiens VKORC1 results in increased susceptibility to Warfarin increases^response to substance 20420818
374 81-81-2 VKORC1 Homo sapiens VKORC1 SNP affects the susceptibility to Warfarin affects^response to substance 24966969|28079798
375 81-81-2 VKORC1 Homo sapiens Warfarin results in decreased activity of VKORC1 protein decreases^activity 14765194|14765195|18240904|18805772|19300499
376 81-81-2 VKORC1 Mus musculus VKORC1 protein polymorphism results in decreased susceptibility to Warfarin decreases^response to substance 27117082
377 81-81-2 VKORC1 Rattus norvegicus VKORC1 protein mutant form affects the susceptibility to Warfarin affects^response to substance 23018795
378 81-81-2 VKORC1L1 Danio rerio Warfarin results in increased expression of VKORC1L1 mRNA increases^expression 25094061
379 81-81-2 YWHAE Mus musculus Warfarin results in increased expression of YWHAE mRNA increases^expression 20493250
380 81-81-2 ZEB1 Homo sapiens Warfarin results in decreased expression of ZEB1 protein decreases^expression 26206560
Serial No.Activity Name DetailsReferences (PubMed)Other details EPA (U.S)Clinical Trials (U.S. NIH)
1 81-81-2 Warfarin

Plant Variety and Essential oils

Serial No.Plant NameVariety NameEssential OilCompound Percentage
1 Mulethi Mishri Glucyrrhiza glabra mulethi essential oil
Print Back

Compound Image

2D Structure

Download



Download Sdf File Download PDB File Download MOL File
View Similar Structures (External DB)
Disclaimer | © Copyright 2020
CSIR-CIMAP